Insulin-like growth factor 1 receptor binding peptides
The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.
1. An isolated polypeptide comprising a polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1-13.
2. An isolated polynucleotide comprising a polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1-13.
3. An isolated polynucleotide comprising a polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 14-26, or a fully complementary sequence thereof.
4. An isolated vector comprising a polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 14-26.
5. The vector of claim 4 , wherein the vector is an expression vector.
6. An isolated host cell comprising the vector of claim 4 .
7. A method of expressing a polypeptide comprising the steps of:
a. providing the host cell of claim 6 ; and
b. culturing the host cell under conditions sufficient for the expression of the polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1-13.
8. An isolated fusion protein comprising a polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1-13 fused to a second polypeptide.
9. The fusion protein of claim 8 , wherein the second polypeptide encodes an immunoglobulin or fragment thereof.
10. A method for in vitro delivery of a therapeutic agent across endothelial cells, comprising:
a. conjugating the therapeutic agent to a polypeptide comprising the polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 8, or 12 to form a conjugate;
b. contacting a polarized monolayer of endothelial cells with the conjugate; and
c. measuring the amount of the conjugate delivered across the endothelial cells.
11. A method for delivery of a therapeutic agent across the blood-brain barrier, comprising:
a. conjugating the therapeutic agent to a polypeptide comprising the polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 8, or 12 to form a conjugate; and
b. administering the conjugate to a mammalian subject.
12. The method of claim 11 wherein the mammalian subject is a human.